Buscar
XORTX Therapeutics Inc
XRTXAñadir a la lista de seguimiento
1.860USD
-0.090-4.62%
Cierre 09-22 16:00（ET）
3.39MCap. mercado
PérdidaP/E TTM
Acerca de XORTX Therapeutics Inc Compañía
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.
Perfil de XORTX Therapeutics Inc
Símbolo de cotizaciónXRTX
Nombre de la empresaXORTX Therapeutics Inc
Fecha de salida a bolsaSep 30, 2015
Director ejecutivoDavidoff (Allen W)
Número de empleados2
Tipo de seguridadOrdinary Share
Fin del año fiscalSep 30
Dirección3710 - 33rd Street NW
CiudadCALGARY
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísCanada
Código postalT2L 2M1
Teléfono14034557727
Sitio Webhttps://www.xortx.com/
Símbolo de cotizaciónXRTX
Fecha de salida a bolsaSep 30, 2015
Director ejecutivoDavidoff (Allen W)
Ejecutivos de XORTX Therapeutics Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Mr. Stacy Evans, M.D.
Mr. Stacy Evans, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mr. Michael Bumby
Mr. Michael Bumby
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Mika Grasso
Mr. Mika Grasso
Co-Chief Executive Officer, Director
Co-Chief Executive Officer, Director
--
--
Mr. Depesh Narotam
Mr. Depesh Narotam
Independent Director
Independent Director
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Ms. Krysta Davies Foss
Ms. Krysta Davies Foss
Director
Director
554.00
--
Dr. Allen W. Davidoff, Ph.D.
Dr. Allen W. Davidoff, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Paul J. Van Damme
Mr. Paul J. Van Damme
Independent Director
Independent Director
--
--
Dr. Stephen Haworth
Dr. Stephen Haworth
Chief Medical Officer
Chief Medical Officer
--
--
Dr. Raymond Dennis (Ray) Pratt, M.D.
Dr. Raymond Dennis (Ray) Pratt, M.D.
Independent Director
Independent Director
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de XORTX Therapeutics Inc?
Los cinco principales accionistas de XORTX Therapeutics Inc son: Ms. Krysta Davies Foss